Table 2

Percentages of participants with SBA titres ≥4 for each of the tested antigens postprimary series and prebooster and postbooster vaccination

Infants with SBA titre ≥4
% (95% CI)
Postprimary (5 months)Prebooster (12 months)Postbooster (13 months)
Group 1 (2+1)Group 2 (3+1)P value*Group 1
(2+1)
Group 2
(3+1)
P value*Group 1
(2+1)
Group 2
(3+1)
P value*
44/76-SL (fHbp)98 (n=55/56)
(90 to 100)
94 (n=59/63)
(85 to 98)
0.3730 (n=17/56)
(19 to 44)
33 (n=20/60)
(22 to 47)
0.8498 (n=56/57)
(91 to 100)
95 (n=52/55)
(85 to 99)
0.36
(5/99) NadA100 (n=56/56)
(94 to 100)
100 (n=63/63)
(94 to 100)
86 (n=49/57)
(74 to 94)
88 (n=53/60)
(77 to 95)
0.79100 (n=58/58)
(94 to 100)
100 (n=57/57)
(94 to 100)
(NZ98/254)
PorA
70 (n=39/56)
(56 to 81)
87 (n=53/61)
(76 to 94)
0.0311 (n=6/57)
(4 to 22)
33 (n=20/60)
(22 to 47)
0.00488 (n=51/58)
(77 to 95)
95 (n=52/55)
(85 to 99)
0.32
  • Blood sampling performed at 5 months (postprimary), 12 months (prebooster), 13 months (postbooster).

  • Results with a p value of <0.05 are highlighted in bold.

  • *Fisher’s exact test.

  • fHbp, factor hour binding protein; GMT, geometric mean titre; NadA, Neisseria adhesin A; PorA, porin A; SBA, serum bactericidal activity.